We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNRX Pharmaceuticals Inc

NRX Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
2.3 USD -0.14 ( 5.74%)
Last update at 2026-11-12T15:44:00Z
VOLUME
269265
Market Cap
147.21M

Momentum Score

…

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.25
Low
2.44
High
52 Week Price Range
1.62
Low
5.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.44
Dividend Yield
-
Revenue TTM
3.39M
Revenue Per Share
0.11
Gross Profit TTM
1.58M
Debt / Equity
-0.04
ROE
-682.61%
Net Debt
-7.17M
ROCE
178.92%
Diluted EPS TTM
-0.50

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -28.62M -25.13M -30.15M -39.82M -93.06M
Net income -28.62M -25.13M -30.15M -35.23M -71.72M
Selling general administrative 13.06M 13.51M 14.22M 27.37M 74.94M
Selling and marketing expenses - - 0.01M - -
Gross profit 0.72M -0.01M -0.01M - -
Reconciled depreciation 0.14M 0.01M 0.01M 0.00M 0.00M
Ebit -27.95M -24.05M -30.03M -44.40M -115.80M
Ebitda -27.81M -24.04M -30.02M -44.65M -115.79M
Depreciation and amortization 0.14M 0.01M 0.01M -0.26M 0.00M
Operating income -16.22M -19.70M -27.59M -44.40M -115.80M
Other operating expenses 17.45M 19.70M 27.59M 44.40M 94.43M
Interest expense 0.67M 1.08M 0.12M -4.58M 0.02M
Tax provision - - - 0.00M 0.00M
Interest income 0.01M 0.04M 0.55M 0.25M -
Net interest income -0.66M -0.19M 0.51M 0.25M -0.02M
Income tax expense - - -0.01M -4.58M -21.35M
Total revenue 1.23M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 16.94M 19.70M 27.58M 44.40M 94.43M
Cost of revenue 0.51M 0.01M 0.01M - -
Total other income expense net -12.40M -5.42M -2.56M 4.58M 22.73M
Net income from continuing ops -28.62M -25.13M -36.06M -39.75M -93.06M
Net income applicable to common shares - - - -39.75M -348.88M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 12.96M 3.65M 7.32M 25.82M 32.73M
Intangible assets 0.93M - - - -
Other current assets 0.93M 1.86M 2.29M 5.74M 5.11M
Total liab 28.89M 26.87M 19.05M 18.41M 11.92M
Total stockholder equity -15.94M -23.22M -11.73M 7.41M 20.81M
Other current liab 23.99M 16.17M 5.25M 5.81M 4.87M
Common stock 0.03M 0.01M 0.08M 0.07M 0.06M
Capital stock 0.03M 0.01M 0.09M 0.07M 0.06M
Retained earnings -306.89M -278.27M -253.15M -223.06M -183.24M
Good will 1.79M 0.00M - - -
Other assets - - - - 0.01M
Cash 7.80M 1.44M 4.59M 20.05M 27.61M
Total current liabilities 28.58M 21.86M 19.05M 16.59M 11.92M
Current deferred revenue - - - - 2.84M
Net debt -7.17M 5.13M 4.57M -9.53M -27.09M
Short term debt 0.32M 1.57M 9.16M 8.70M 0.52M
Short long term debt - 1.57M 9.16M 7.70M 0.52M
Short long term debt total 0.63M 6.58M 9.16M 10.53M 0.52M
Other stockholder equity 290.93M 255.03M 241.33M 230.40M 203.99M
Total current assets 8.89M 3.30M 6.88M 25.80M 32.71M
Long term investments 0.40M 0.00M - - -
Net tangible assets - - - 7.41M 20.81M
Net receivables 0.16M 0.00M 0.01M 0.01M 0.00M
Long term debt - 5.01M - 2.82M -
Inventory - - -0.01M -0.01M -
Accounts payable 4.27M 4.13M 4.63M 2.08M 3.69M
Accumulated other comprehensive income - - -0.00M - -
Non currrent assets other 0.32M 0.35M 0.43M 0.02M 0.01M
Non current assets total 4.06M 0.35M 0.43M 0.02M 0.01M
Capital lease obligations 0.63M 0.00M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.43M 0.00M -0.00M -0.01M -0.01M
Change to liabilities - - - 0.00M -0.02M
Total cashflows from investing activities -2.81M - -0.00M -0.01M -0.01M
Net borrowings 4.68M -1.50M -3.09M - -1.28M
Total cash from financing activities 23.28M 7.49M 6.20M 32.21M 63.46M
Change to operating activities - - - 2.31M -5.71M
Net income -28.62M -25.13M -30.15M -39.75M -93.06M
Change in cash 6.35M -3.15M -15.46M -7.55M 25.75M
Begin period cash flow 1.44M 4.59M 20.05M 27.61M 1.86M
End period cash flow 7.80M 1.44M 4.59M 20.05M 27.61M
Total cash from operating activities -14.11M -10.64M -21.66M -39.76M -37.70M
Issuance of capital stock 15.86M 5.91M 9.38M 22.70M 36.98M
Depreciation 0.14M 0.01M 0.01M 0.00M 0.00M
Other cashflows from investing activities -0.43M - - - -
Change to account receivables 0.05M 0.00M - 0.00M 0.83M
Other cashflows from financing activities -0.35M 3.07M 1.17M 10.03M 27.75M
Change to netincome - - - - 60.26M
Capital expenditures 0.00M 0.00M 0.00M 0.01M 0.01M
Change in working capital 1.41M 5.29M 5.16M 0.70M -4.90M
Stock based compensation 0.23M 0.49M 0.39M 3.63M 7.79M
Other non cash items 12.73M 8.71M 2.94M -4.33M 54.28M
Free cash flow -14.11M -10.64M -21.66M -39.77M -37.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NRXP
NRX Pharmaceuticals Inc		 -0.14
5.74%		 2.30 - 34.25 43.37 2.90 37.15 -0.15
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

1201 N. Market Street, Wilmington, DE, United States, 19801

484 254 6134

https://www.nrxpharma.com

29

Name Title Year Born
Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chief Scientist & Director 1957
Mr. Robert Besthof M.I.M. Head of Operations, Chief Commercial & Patient Officer 1966
Mr. Stephen H. Willard Esq. CEO & Director 1961
Prof. Daniel C. Javitt Co-Founder & Chairman of Scientific Advisory Board NA
Dr. Seth L. Van Voorhees Ph.D. CFO & Treasurer 1961
Suzanne Messere Investor Relations NA
Dr. Michael Kunz Gen. Counsel & Corp. Sec. 1965
Ms. Molly Cogan Sr. Director of Global Communications & Gov. Affairs NA
Dr. Philip T. Lavin Ph.D. Chief Methodologist 1947
Dr. Dennis K. McBride Ph.D. Chief Strategy Officer & Sr. Scientist NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…